Last reviewed · How we verify
NCT05066776
Liquid Biopsy With PET/CT Versus PET/CT Alone in Diagnosis of Small Lung Nodules
trial in Lung Cancer in 31 participants. Terminated before completion.
1 February 2023
Quick facts
| Lead sponsor | Palo Alto Veterans Institute for Research |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 31 |
| Start date | 23 September 2021 |
| Primary completion | 1 February 2023 |
| Estimated completion | 1 February 2023 |
| Sites | 1 location across United States |
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
- Solitary Pulmonary Nodule — all drugs for Solitary Pulmonary Nodule →
- Multiple Pulmonary Nodules — all drugs for Multiple Pulmonary Nodules →
Sponsor
Palo Alto Veterans Institute for Research
Who can join
18 and older, any sex, with Lung Cancer or Solitary Pulmonary Nodule. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine if a liquid biopsy, a method of detecting cancer from a blood draw, combined with a PET/CT scan, a type of radiological scan, is better at determining whether a lung nodule is cancerous when compared to a PET/CT scan alone. A PET/CT scan is already used for diagnosis of lung nodules, but its efficacy is uncertain in nodules 6-20 mm in size. Therefore, the PET/CT will be evaluated for its diagnostic ability in lesions this size alone and in combination with a liquid biopsy. Secondarily, a machine learning model will be created to see if the combination of the PET/CT imaging data and the liquid biopsy data can predict the presence of cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05066776
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other Palo Alto Veterans Institute for Research trials
Trials by the same sponsor.
- NCT07219251 — Engagement of Veterans With Lung Cancer · NA · recruiting
- NCT06704061 — Online Yoga vs Acceptance and Commitment Therapy for Treating Chronic Musculoskeletal Pain · NA · recruiting
- NCT07069517 — Accelerated Treatment for Co-occurring Insomnia, Nightmares, and PTSD · NA · recruiting
- NCT07303725 — Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology · recruiting
- NCT07303712 — Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05066776 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Palo Alto Veterans Institute for Research
- Last refreshed: 8 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05066776.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing